Roivant Sciences (ROIV) Unveils New Pipeline Program Mosliciguat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Roivant Sciences (ROIV) PT Raised to $12.50 at BofA Securities
September 11, 2024 5:18 AM EDTBofA Securities analyst Chi Fong raised the price target on Roivant Sciences (NASDAQ: ROIV) to $12.50 (from $12.00) while maintaining a Neutral rating.
The analyst comments "Roivant (ROIV) disclosed a new Ph2-ready program, mosliciguat, for interstitial lung disease (PH-ILD). We think the Ph1... More
